Research progress on fecal microbiota transplantation in the treatment of irritable bowel syndrome
-
摘要: 肠易激综合征(irritable bowel syndrome，IBS)是一种常见的胃肠道疾病，其不仅对患者的日常生活产生影响，还会对社会经济造成巨大消耗和浪费。主要表现为腹泻、便秘或腹痛腹胀等症状交替，而且这些症状不能简单用结构或生化异常来解释，目前其发病机制和病理生理机制尚不清楚。粪菌移植是通过将健康者的粪菌提取物通过胃肠镜或胶囊等形式植入到IBS患者胃肠道从而缓解症状的技术，本文对粪菌移植治疗IBS的研究进展和可能机制进行综述，并对该项技术的应用前景及可能出现的问题进行分析。Abstract: Irritable bowel syndrome (IBS) is a common gastrointestinal disease that not only affects the daily life of patients, but also causes significant consumption and waste to the social economy. It mainly manifests as alternating signs of diarrhea, constipation, or abdominal pain and bloating, and these signs cannot be adequately explained by structural or biochemical abnormalities alone. Therefore, the pathogenesis and pathophysiological mechanisms of IBS remain unclear to date. Faecal microbiome transplantation (FMT) is a technique that alleviates gastrointestinal symptoms by transplanting fecal microbiome from healthy individuals into the gastrointestinal tract of IBS patients through gastroscopy or capsules. This article will provide a review of the research progress and possible mechanisms of FMT treatment for IBS, as well as a summary of the application prospects and potential issues of this technology.
-
Key words:
- fecal microbiota transplantation /
- irritable bowel syndrome /
- brain-gut axis /
- treatment
-
-
[1] Camilleri M. Management Options for Irritable Bowel Syndrome[J]. Mayo Clin Proc, 2018, 93(12): 1858-1872. doi: 10.1016/j.mayocp.2018.04.032
[2] Adriani A, Ribaldone DG, Astegiano M, et al. Irritable bowel syndrome: the clinical approach[J]. Panminerva Med, 2018, 60(4): 213-222.
[3] Singh P, Alm EJ, Kelley JM, et al. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant(FMT)in IBS-D[J]. Gut Microbes, 2022, 14(1): 2020067. doi: 10.1080/19490976.2021.2020067
[4] Zhang F, Luo W, Shi Y, et al. Should We Standardize the 1, 700-Year-Old Fecal Microbiota Transplantation?[J]. Am J Gastroenterol, 2012, 107(11): 1755-1756.
[5] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections[J]. Am J Gastroenterol, 2013, 108(4): 478-498;quiz 499. doi: 10.1038/ajg.2013.4
[6] Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464(7285): 59-65. doi: 10.1038/nature08821
[7] Adak A, Khan MR. An insight into gut microbiota and its functionalities[J]. Cell Mol Life Sci, 2019, 76(3): 473-493. doi: 10.1007/s00018-018-2943-4
[8] Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome[J]. Lancet Gastroenterol Hepatol, 2016, 1(2): 133-146. doi: 10.1016/S2468-1253(16)30023-1
[9] Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report[J]. Gut, 2013, 62(1): 159-176. doi: 10.1136/gutjnl-2012-302167
[10] Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota[J]. Curr Opin Endocrinol Diabetes Obes, 2020, 27(1): 28-35. doi: 10.1097/MED.0000000000000523
[11] Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome[J]. Gastroenterology, 2011, 141(5): 1792-1801. doi: 10.1053/j.gastro.2011.07.043
[12] Martin CR, Osadchiy V, Kalani A, et al. The Brain-Gut-Microbiome Axis[J]. Cell Mol Gastroenterol Hepatol, 2018, 6(2): 133-148. doi: 10.1016/j.jcmgh.2018.04.003
[13] Cheung SG, Goldenthal AR, Uhlemann AC, et al. Systematic Review of Gut Microbiota and Major Depression[J]. Front Psychiatry, 2019, 10: 34.
[14] Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression[J]. Nat Microbiol, 2019, 4(4): 623-632. doi: 10.1038/s41564-018-0337-x
[15] Moran GW, Leslie FC, Levison SE, et al. Review: Enteroendocrine cells: Neglected players in gastrointestinal disorders?[J]. Therap Adv Gastroenterol, 2008, 1(1): 51-60. doi: 10.1177/1756283X08093943
[16] Moran-Ramos S, Tovar AR, Torres N. Diet: Friend or Foe of Enteroendocrine Cells: How It Interacts with Enteroendocrine Cells[J]. Adv in Nutr, 2012, 3(1): 8-20. doi: 10.3945/an.111.000976
[17] Sternini C, Anselmi L, Rozengurt E. Enteroendocrine cells: a site of 'taste' in gastrointestinal chemosensing[J]. Curr Opin Endocrinol Diabetes Obes, 2008, 15(1): 73-78. doi: 10.1097/MED.0b013e3282f43a73
[18] El-Salhy M, Mazzawi T, Hausken T, et al. Interaction between diet and gastrointestinal endocrine cells(Review)[J]. Biomed Rep, 2016, 4(6): 651-656. doi: 10.3892/br.2016.649
[19] Mazzawi T, El-Salhy M. Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome(Review)[J]. Int J Mol Med, 2017, 40(4): 943-952. doi: 10.3892/ijmm.2017.3096
[20] Mazzawi T, Hausken T, Gundersen D, et al. Dietary guidance normalizes large intestinal endocrine cell densities in patients with irritable bowel syndrome[J]. Eur J Clin Nutr, 2016, 70(2): 175-181. doi: 10.1038/ejcn.2015.191
[21] Mazzawi T, Hausken T. Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation[J]. Scand J Gastroenterol, 2022, 57(7): 792-796. doi: 10.1080/00365521.2022.2036809
[22] Aziz MNM, Kumar J, Muhammad Nawawi KN, et al. Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain[J]. Nutrients, 2021, 13(9): 3061. doi: 10.3390/nu13093061
[23] Shariati A, Fallah F, Pormohammad A, et al. The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome[J]. J Cell Physiol, 2019, 234(6): 8550-8569. doi: 10.1002/jcp.27828
[24] Holster S, Hooiveld GJ, Repsilber D, et al. Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome[J]. Biomolecules, 2019, 9(10): 586. doi: 10.3390/biom9100586
[25] Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood[J]. Gastroenterology, 2021, 160(5): 1486-1501. doi: 10.1053/j.gastro.2020.10.066
[26] Cryan JF, O'riordan KJ, Cowan CSM, et al. The Microbiota-Gut-Brain Axis[J]. Physiol Rev, 2019, 99(4): 1877-2013. doi: 10.1152/physrev.00018.2018
[27] Jang SH, Woo YS, Lee SY, et al. The Brain-Gut-Microbiome Axis in Psychiatry[J]. Int J Mol Sci, 2020, 21(19): 7122. doi: 10.3390/ijms21197122
[28] Lopez-Siles M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics[J]. ISME J, 2017, 11(4): 841-852. doi: 10.1038/ismej.2016.176
[29] El-Salhy M, Valeur J, Hausken T, et al. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome[J]. Neurogastroenterol Motil, 2021, 33(2): e13983. doi: 10.1111/nmo.13983
[30] Xu HM, Huang HL, Xu J, et al. Cross-Talk Between Butyric Acid and Gut Microbiota in Ulcerative Colitis Following Fecal Microbiota Transplantation[J]. Front Microbiol, 2021, 12: 658292. doi: 10.3389/fmicb.2021.658292
[31] Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short-and Long-term Results From a Placebo-Controlled Randomized Trial[J]. Gastroenterology, 2021, 160(1): 145-157. doi: 10.1053/j.gastro.2020.07.013
[32] Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study[J]. Gut, 2018, 67(12): 2107. doi: 10.1136/gutjnl-2018-316434
[33] Lahtinen P, Jalanka J, Hartikainen A, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2020, 51(12): 1321-1331. doi: 10.1111/apt.15740
[34] Holster S, Lindqvist CM, Repsilber D, et al. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study[J]. Clin Transl Gastroenterol, 2019, 10(4): e00034. doi: 10.14309/ctg.0000000000000034
[35] Jamshidi P, Farsi Y. Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Int J Mol Sci, 2023, 14: 1136343.
[36] Hamazaki M, Sawada T, Yamamura T, et al. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan[J]. BMC Gastroenterol, 2022, 22(1): 342. doi: 10.1186/s12876-022-02408-5
[37] Huang HL, Chen HT, Luo QL, et al. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota[J]. J Dig Dis, 2019, 20(8): 401-408. doi: 10.1111/1751-2980.12756
[38] El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(5): 439-445. doi: 10.1080/17474124.2018.1447380
[39] El-Salhy M, Winkel R, Casen C, et al. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation[J]. Gastroenterology, 2022, 163(4): 982-994. e914. doi: 10.1053/j.gastro.2022.06.020
[40] El-Salhy M, Gilja OH, Hatlebakk JG. Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome[J]. Neurogastroenterol Motil, 2024, 36(1): e14641. doi: 10.1111/nmo.14641
[41] El-Salhy M, Hausken T, Hatlebakk JG. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation(FMT)Increases the Response in Patients with Irritable Bowel Syndrome(IBS)[J]. Nutrients, 2019, 11(6): 1415. doi: 10.3390/nu11061415
[42] Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota Transplantation[J]. PLoS One, 2016, 11(8): e0161174. doi: 10.1371/journal.pone.0161174
[43] Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature[J]. J Hosp Infect, 2016, 92(2): 117-127. doi: 10.1016/j.jhin.2015.10.024
[44] El-Salhy M, Hatlebakk JG, Gilja OH, et al. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study[J]. Gut, 2020, 69(5): 859-867. doi: 10.1136/gutjnl-2019-319630
[45] Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4): 569-580. doi: 10.1136/gutjnl-2016-313017
-
计量
- 文章访问数: 442
- PDF下载数: 109
- 施引文献: 0
下载: